Management of inflammatory bowel disease in France: a nationwide survey among private gastroenterologists

Introduction : Les données sur la gestion actuelle des patients atteints de maladie inflammatoire chronique intestinale (MICI) sont rares. Matériel et méthodes : Il s’agissait d’une enquête nationale sur internet réalisée auprès de gastro-entérologues libéraux sous forme de questions à choix multiples en Juin 2012. Résultats : 375 patients atteints de MICI ont été inclus : 48 % d’entre eux avaient une rectocolite hémorragique (RCH). Un antécédent d’hospitalisation concernait un tiers des patients atteints de MICI, et un antécédent de chirurgie 40 % des patients atteints de maladies de Crohn (MC). Deux tiers des patients avaient une maladie active le jour de la consultation (l’activité de la maladie était jugée par le médecin sans score). Soixante pour cent des patients atteints de RCH étaient traités par 5-aminosalicylés contre 18,5 % de MC (p<0,001). Parmi les patients traités par anti-TNF, seulement 4,5 % recevaient un traitement concomitant par immunomodulateur. La moitié des patients avaient eu une coloscopie dans l’année. Concernant le dépistage du cancer colorectal, des biopsies étagées et la chromoendoscopie étaient réalisées dans respectivement 75 % et 40 % des cas. Un score endoscopique d’activité n’était utilisé que chez 10 % des patients. Environ un tiers des patients ayant une MICI avait eu une imagerie dans l’année : l’entéro-IRM représentait environ la moitié de ces prescriptions. Le scanner a été prescrit chez 12 % des patients et l’échographie chez seulement 7 %. Conclusion : De nombreux patients ont encore une maladie active à l’ère des biothérapies, et la proportion de patients recevant une association anti-TNF et azathioprine reste faible en médecine libérale. La coloscopie est toujours la référence pour évaluer l’activité des MICI même si l’IRM est de plus en plus pratiquée. La chromoendoscopie et les scores endoscopiques sont encore sous-utilisés.Background: Data on the current management of inflammatory bowel disease (IBD) are scarce. Materials and Methods: This was a web-based nationwide survey consisting of multiple-choice questions among private gastroenterologists in France in June 2012. Results: 375 IBD patients were analyzed: 48% had ulcerative colitis (UC). History of hospitalization concerned one third of IBD patients, and history of surgery 40% of Crohn’s disease patients (CD). Two thirds of IBD patients had active disease (disease activity was judged by the physician without using a validated tool or a score). The proportion of patients treated with anti-TNF therapy was significantly lower in UC (18.9%) than in CD (38.9 %; p<0.0001). Sixty per cent of UC patients were treated with 5-aminosalicylates as compared with 18.5% of in CD (p<0.0001). Among anti-TNF treated patients, only 4.5% were receiving concomitant immunomodulator. Half of IBD patients had a colonoscopy within the past year. Regarding colorectal cancer screening, random biopsies and chromoendoscopy were performed in 75% and 40% of cases, respectively. An endoscopic score was used for only 10% of IBD patients. About one third of IBD patients had imaging studies within the past year, MRI enterography representing about half of them. Abdominal CT was prescribed for 12% of IBD patients and abdominal ultrasound for only 7% of them. Conclusions: Many patients still have active disease in the biologics era despite an increasing use of immunosuppressive therapy, and the number of patients receiving combination therapy is low in private practice. Colonoscopy remains the gold standard to assess IBD even though MRI is increasingly used in these patients. Chromoendoscopy and endoscopy scores are not often used

Régime sans gluten

Tuberculosis, despite its prevention, remains an endemic affection in Morocco. Although rare, pseudo surgical forms and especially peritonitis are mainly due to delayed diagnosis. We report the case of a 30-year-old woman, admitted for peritonitis. The diagnosis of tuberculous peritonitis was established during surgery with macroscopic observation of granulations, and confirmed after biopsy specimens by identification of a giant lymph node cell granuloma with caseous necrosis. Outcome was favorable after appropriate antibiotic therapy. This observation emphasizes the fact that peritonitis, although a rare complication of peritoneal tuberculosis, poses problems of positive and differential diagnosis. Even if treatment is based on antituberculous quadritherapy, surgery is sometimes necessary and should be decided in due time

Risques et adaptation nutritionnelle en cancérologie

This article starts with a presentation of Caycedian Sophrology. We then evaluate its impact on stress reduction through a questionnaire on a students’ population. It appears that stress level increases between the two sessions in the control group while it decreases in the experimental group

Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures

International audienceThe use of direct oral anticoagulants (DOACs) was an important step forward in the management of atrial fibrillation and venous thromboembolism (VTE). The DOACs, anti-IIa for dabigatran and anti-Xa for rivaroxaban, apixaban and edoxaban, all have a rapid onset of action and a short half life. There is no need for routine hemostasis testing for treatment monitoring of a DOAC. Compared with vitamin K antagonists (VKAs), DOACs may increase the risk of gastrointestinal bleeding (relative risk 1.25). Withholding the DOAC treatment, evaluating the time of the last intake and estimating the patient’s renal function are the first steps in the management of gastrointestinal bleeding. For patients without impaired renal function, achieving low coagulation takes around 24 h after the last intake of a DOAC. The use of DOAC antagonists will be helpful in controlling bleeding in the most severe and urgent situations. Idarucizumab is available for clinical use for dabigatran and andexanet is currently being reviewed by drug agencies for rivaroxaban, apixaban and edoxaban. It is important to assess the bleeding risk associated with the planned procedure, and the patient’s renal function before withholding DOAC therapy for a scheduled intervention. It is mandatory to strengthen the local hemostasis strategies in DOAC-treated patients undergoing a therapeutic endoscopic procedure. Resuming or not resuming anticoagulation with a DOAC after bleeding or a risky procedure depends on the thrombotic and bleeding risk as well as the procedure involved. This discussion should always involve the cardiologist and decisions should be taken by a pluridisciplinary team

Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study

Background: Gastrointestinal angiodysplasias (GIADs) could be responsible for recurrent bleeding and severe anemia. Somatostatin analogs could reduce transfusion requirements in these patients but no randomized controlled study is available. The main objective of the ANGIOPAS phase II double-blinded randomized, noncomparative study was to assess the effectiveness of pasireotide-LAR in reducing transfusion requirements in patients with refractory GIADs bleeding. Methods: A total of 22 patients with transfusion requirements ⩾6 units of packed red blood cells (pRBCs) during the 6 months prior to inclusion were randomized to receive pasireotide-LAR 60 mg ( n = 10) or placebo ( n = 12) every 28 days for 6 months. Patients were then followed for an additional 6 months after stopping treatment. Results: The pasireotide-LAR and placebo groups were equivalent for age, sex, comorbidities and transfusion requirement during the reference period (median 13 and 9.5 pRBCs). A 50 and 83% success rate (success defined as a decrease of at least 30% of transfused pRBCs) was observed in the pasireotide-LAR arm in the Intent to Treat (ITT) and per protocol (PP) analysis respectively. The need for transfusion during the intervention period was 3 pRBC units in the pasireotide-LAR group (range 0–26) and 11.5 pRBC units in the placebo group (range 0–23). Overall, three cases with glycemic control impairment were observed in the pasireotide-LAR group including one de novo diabetes. Conclusion: This double-blinded noncomparative randomized phase II study suggests, for the first time, the effectiveness of pasireotide-LAR 60 mg every 28 days to decrease the transfusion requirement in patients with recurrent bleeding due to GIADs

Efficacy and safety of pasireotide-LAR for the treatment of refractory bleeding due to gastrointestinal angiodysplasias: results of the ANGIOPAS multicenter phase II noncomparative prospective double-blinded randomized study

Background: Gastrointestinal angiodysplasias (GIADs) could be responsible for recurrent bleeding and severe anemia. Somatostatin analogs could reduce transfusion requirements in these patients but no randomized controlled study is available. The main objective of the ANGIOPAS phase II double-blinded randomized, noncomparative study was to assess the effectiveness of pasireotide-LAR in reducing transfusion requirements in patients with refractory GIADs bleeding. Methods: A total of 22 patients with transfusion requirements ⩾6 units of packed red blood cells (pRBCs) during the 6 months prior to inclusion were randomized to receive pasireotide-LAR 60 mg ( n = 10) or placebo ( n = 12) every 28 days for 6 months. Patients were then followed for an additional 6 months after stopping treatment. Results: The pasireotide-LAR and placebo groups were equivalent for age, sex, comorbidities and transfusion requirement during the reference period (median 13 and 9.5 pRBCs). A 50 and 83% success rate (success defined as a decrease of at least 30% of transfused pRBCs) was observed in the pasireotide-LAR arm in the Intent to Treat (ITT) and per protocol (PP) analysis respectively. The need for transfusion during the intervention period was 3 pRBC units in the pasireotide-LAR group (range 0–26) and 11.5 pRBC units in the placebo group (range 0–23). Overall, three cases with glycemic control impairment were observed in the pasireotide-LAR group including one de novo diabetes. Conclusion: This double-blinded noncomparative randomized phase II study suggests, for the first time, the effectiveness of pasireotide-LAR 60 mg every 28 days to decrease the transfusion requirement in patients with recurrent bleeding due to GIADs

Management of gastrointestinal stromal tumours of limited size: proposals from a French panel of physicians.

International audienceA number of guidelines on the management of gastro-intestinal stromal tumours (GISTs) have been published, mostly based on expert consensus. However, these guidelines have generally failed to address the specific problem of GISTs of limited size (i.e. those measuring a few centimetres in diameter) with which gastroenterologists are increasingly confronted. The aim of the present work was to draw up proposals for the diagnosis and treatment of GISTs measuring less than 5 cm in diameter. For this purpose, a number of practical questions were put to a panel of French experts